Wolters Kluwer announces two senior executive appointments
Wolters Kluwer, a global leader in information, software, and services for professionals, today announced Atul Dubey as General Manager of its Finance, Risk and Regulatory Reporting (FRR) business, part of its Corporate Performance & ESG (CP & ESG) division. Suzanne Konstance will succeed Dubey as General Manager of Wolters Kluwer Legal & Regulatory U.S, part of the company’s Legal & Regulatory division, effective May 1.
Karen Abramson, CEO of Wolters Kluwer CP & ESG, commented: “Atul’s deep understanding of the financial regulatory and risk landscape will be critical strengths as he takes this global leadership role for Wolters Kluwer FRR, driving growth and relentless innovation for our clients.”
Wolters Kluwer FRR’s award-winning OneSumX suite of solutions support financial institutions through innovative technology that enables and empowers clients to stay compliant with everchanging regulatory requirements, manage uncertainty through financial risk management offerings and drive efficiency.
“Serving over 800 customers in 40 countries, OneSumX for FRR has a significant global role in the financial services ecosystem,” Dubey commented. “I look forward to working with Karen and the talented team to drive product enhancement and innovation, delivering value to our clients, partners and regulators.”
Dubey joined Wolters Kluwer in 2016 as Chief Strategy Officer, with a strong background in institutional banking, having held senior leadership roles at Citigroup, S&P Global and Booz Allen.
Martin O’Malley, CEO of Wolters Kluwer Legal & Regulatory: “I am grateful for Atul’s incisive leadership, which has seen our solutions, services and customers thrive during a period of unparalleled transformation for our industry. At the same time, I am excited to welcome Suzanne to our division. Her deep industry expertise, commitment to innovation and experience in creating vibrant team cultures will continue to push our U.S. business to new heights.”
Konstance held leadership positions in Wolters Kluwer for eight years, in which she built a strong track record in product management, strategy and go-to-market. She most recently served as Vice President & Segment Leader of Lien Solutions for the Wolters Kluwer Compliance Solutions business unit – a part of the company’s Financial & Corporate Compliance (FCC) division. She successfully engaged in launching AI-enabled products to transform the business while managing to achieve an above-market growth rate. Prior to joining Wolters Kluwer, Konstance held senior roles at Pitney Bowes, Citibank, and MetLife.
“By combining unparalleled domain expertise with the latest AI-driven technology, Wolters Kluwer Legal & Regulatory U.S. is uniquely positioned to help today’s legal professionals achieve measurable efficiencies and gain valuable insights,” Konstance said. “I am eager to begin collaborating with this dynamic team as we chart a path toward continued growth.”
Wolters Kluwer Legal & Regulatory U.S. is a leading provider of information, business intelligence, and regulatory and legal workflow solutions for legal, corporate, and compliance professionals across several industries. Legisway, Wolters Kluwer’s award-winning and all-in-one SaaS legal information and contract management solution for corporate legal departments, recently launched new AI-enhanced functionality, accelerating the contract review process by enabling legal departments to effortlessly query their contracts using advanced natural language processing.
For more information about Wolters Kluwer, please visit: www.wolterskluwer.com
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.
Wolters Kluwer reported 2023 annual revenues of €5.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,400 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417358923/en/
Contact information
Media
Sarah Whybrow
Associate Director, External Communications
Corporate Performance & ESG
Wolters Kluwer
Mob: +44 7855 186713
sarah.whybrow@wolterskluwer.com
Frank Ready
Manager, External Communications
Legal & Regulatory
Wolters Kluwer
Office: 717-205-3647
Email: Frank.Ready@wolterskluwer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom